| 0.425 -0.127 (-23.04%) | 01-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.51 |
1-year : | 6.35 |
| Resists | First : | 4.72 |
Second : | 5.44 |
| Pivot price | 4.26 |
|||
| Supports | First : | 3.56 |
Second : | 2.97 |
| MAs | MA(5) : | 4 |
MA(20) : | 4.41 |
| MA(100) : | 5.71 |
MA(250) : | 6.94 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 12.3 |
D(3) : | 10.7  |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 16 | Low : | 0.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IDRA ] has closed below the lower bollinger band by 17.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ IDRA ] is to continue within current trading range. It is unclear right now based on current values. 72.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.21 - 4.24 | 4.24 - 4.26 |
| Low: | 4.07 - 4.09 | 4.09 - 4.11 |
| Close: | 4.12 - 4.16 | 4.16 - 4.2 |
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Tue, 23 Apr 2024
Here's Why Idera Pharmaceuticals Fell as Much as 15.4% Today - Yahoo Movies UK
Wed, 28 Sep 2022
Idera Pharmaceuticals Acquires Aceragen - GlobeNewswire
Tue, 17 May 2022
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam ... - GlobeNewswire
Thu, 31 Mar 2022
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - GlobeNewswire
Tue, 14 Dec 2021
Idera Pharmaceuticals Announces Tilsotolimod Updates - GlobeNewswire
Thu, 18 Mar 2021
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | -0.12 |
| EPS Est This Year | -0.48 |
| EPS Est Next Year | -0.5 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.18 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2018-07-29 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|